Pharma BD Deal Intelligence
Sanofi SA / EVOQ Therapeutics, Inc.
2025 · Licensing/Option · $500M · Complete
Sanofi and EVOQ Therapeutics entered a collaboration and license agreement built on EVOQ's NanoDisc technology, which selectively targets dendritic cells to restore natural immune tolerance pathways for autoimmune diseases. The companies will jointly conduct research activities while Sanofi leads development and commercialization worldwide. Total consideration could reach $500 million across an upfront payment plus preclinical, development and sales milestones, with tiered royalties on product sales. The upfront amount was not disclosed.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.
Key facts
- Announced Oct 16, 2025
- Deal value $500M
- Deal type Licensing/Option
- Therapeutic area Immunology
- Indications Autoimmune diseases
- Key assets NanoDisc immune-tolerance platform programs (undisclosed targets)
- Mechanism Dendritic-cell-targeted NanoDisc antigen delivery to restore immune tolerance
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals · Sanofi SA deals · Immunology deals